Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

NCT01355003 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01355003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01355003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Observational
Overall status
Terminated
Start date
February 29, 2008
Completion date
June 30, 2010
Enrollment
1,080 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

papillomavirus infections